{"id":927660,"date":"2026-01-15T10:36:58","date_gmt":"2026-01-15T15:36:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\/"},"modified":"2026-01-15T10:36:58","modified_gmt":"2026-01-15T15:36:58","slug":"60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\/","title":{"rendered":"60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio"},"content":{"rendered":"
\n

WASHINGTON, Jan. 15, 2026 (GLOBE NEWSWIRE) — 60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) (\u201c60 Degrees Pharma\u201d or the \u201cCompany\u201d), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it will effect a one-for-four (1:4) reverse stock split (the “reverse split”) of its common stock, par value $0.0001 per share (the “Common Stock”), that will become effective on January 20, 2026, at 12:01 AM Eastern Time, before the opening of trading on The Nasdaq Capital Market (“Nasdaq”). 60 Degrees Pharma has requested that its Common Stock begin trading on January 20, 2026, on a post-reverse split basis on the Nasdaq under the existing symbol “SXTP”.<\/p>\n

The reverse split is primarily intended to bring 60 Degrees Pharma into compliance with the minimum bid price requirement for maintaining its listing on the Nasdaq. The new CUSIP number for the Common Stock following the reverse split will be 83006G500.<\/p>\n

At 60 Degree Pharma\u2019s special meeting of stockholders on October 8, 2025 (the “Special Meeting”), 60 Degree Pharma\u2019s stockholders approved the proposal to authorize 60 Degree Pharma\u2019s board of directors (the “Board”), in its sole and absolute discretion, to file a certificate of amendment (the “Amendment”) to 60 Degree Pharma\u2019s amended and restated certificate of incorporation to effect the reverse split of the Company at a ratio of one-to-four (1:4). On December 17, 2025, the Board approved the reverse split at a ratio of one-to-four (1:4), and the Amendment has been filed with the Secretary of State of the State of Delaware, which will become effective on January 20, 2026, at 12:01 AM Eastern Time, before the opening of trading on Nasdaq.<\/p>\n

The reverse split will affect all issued and outstanding shares of Common Stock. All outstanding options, restricted stock awards, warrants and other securities entitling their holders to purchase or otherwise receive shares of Common Stock will be adjusted as a result of the reverse split, as required by the terms of each security. The number of shares available to be awarded under any Equity Incentive Plan, will also be appropriately adjusted. Following the reverse split, the par value of the Common Stock will remain unchanged at $0.0001 per share. The reverse split will not change the authorized number of shares of Common Stock or preferred stock. No fractional shares of Common Stock shall be issued as a result of the Reverse Split, and stockholders who otherwise would be entitled to receive fractional shares of New Common Stock shall be entitled to receive the number of shares of New Common Stock rounded up to the next whole number. The reverse split will affect all stockholders uniformly and will not alter any stockholder’s percentage interest in 60 Degree Pharma\u2019s equity (other than as a result of the rounding of fractional shares, as set forth above).<\/p>\n

The reverse split will reduce the number of shares of Common Stock issued and outstanding from approximately 5,148,767 to approximately 1,287,192.<\/p>\n

\n About\u00a060\u00a0Degrees Pharmaceuticals, Inc.<\/strong>\n <\/p>\n

60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and commercializing new medicines for the treatment and prevention of vector-borne disease. The Company achieved\u00a0U.S. Food and Drug Administration\u00a0approval of Its lead product, ARAKODA\u00ae<\/sup>\u00a0(tafenoquine<\/strong>), for malaria prevention in 2018. ARAKODA is commercially available in the\u00a0U.S.\u00a0and\u00a0Australia.\u00a060 Degrees Pharmaceuticals, Inc.\u00a0also collaborates with prominent research and academic organizations in the\u00a0U.S.\u00a0and\u00a0Australia.\u00a060 Degrees Pharmaceuticals, Inc.\u00a0is headquartered in\u00a0Washington, D.C., with a subsidiary in\u00a0Australia. Learn more at\u00a0www.60degreespharma.com<\/u><\/a>.<\/p>\n

The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management\u2019s current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.<\/p>\n

\n Cautionary Note Regarding Forward-Looking Statements<\/strong>\n <\/p>\n

This press release may contain \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the\u00a0U.S.\u00a0Private Securities Litigation Reform Act of 1995. Forward\u2010looking statements reflect the current view about future events. When used in this press release, the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cfuture,\u201d \u201cintend,\u201d \u201cplan,\u201d or the negative of these terms and similar expressions, as they relate to us or our management, identify forward\u2010looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs,\u00a0expectations\u00a0and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for\u00a0tafenoquine<\/strong>\u00a0(ARAKODA\u00ae<\/sup>\u00a0or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials or patient recruitment in our trials might be slow or negligible; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market.\u00a0More detailed information about the Company and the risk factors that may affect the realization of forward- looking statements is set forth in the Company\u2019s filings with the\u00a0Securities and Exchange Commission\u00a0(\u201cSEC\u201d), including the information contained in our Annual Report on Form 10-K filed with the\u00a0SEC\u00a0on\u00a0April 1, 2024, and our subsequent\u00a0SEC\u00a0filings. Investors and security holders are urged to read these documents free of charge on the SEC\u2019s website at\u00a0www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, the Company\u2019s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.<\/p>\n

Investor Contact:
Patrick Gaynes
patrickgaynes@60degreespharma.com<\/u><\/a><\/p>\n

Source: Sixty Degrees Pharmaceuticals<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

WASHINGTON, Jan. 15, 2026 (GLOBE NEWSWIRE) — 60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) (\u201c60 Degrees Pharma\u201d or the \u201cCompany\u201d), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it will effect a one-for-four (1:4) reverse stock split (the “reverse split”) of its common stock, par value $0.0001 per share (the “Common Stock”), that will become effective on January 20, 2026, at 12:01 AM Eastern Time, before the opening of trading on The Nasdaq Capital Market (“Nasdaq”). 60 Degrees Pharma has requested that its Common Stock begin trading on January 20, 2026, on a post-reverse split basis on the Nasdaq under the existing symbol “SXTP”. The reverse split is primarily intended to bring 60 Degrees … <\/p>\n

Continue reading “60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-927660","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\n60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WASHINGTON, Jan. 15, 2026 (GLOBE NEWSWIRE) — 60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) (\u201c60 Degrees Pharma\u201d or the \u201cCompany\u201d), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it will effect a one-for-four (1:4) reverse stock split (the “reverse split”) of its common stock, par value $0.0001 per share (the “Common Stock”), that will become effective on January 20, 2026, at 12:01 AM Eastern Time, before the opening of trading on The Nasdaq Capital Market (“Nasdaq”). 60 Degrees Pharma has requested that its Common Stock begin trading on January 20, 2026, on a post-reverse split basis on the Nasdaq under the existing symbol “SXTP”. The reverse split is primarily intended to bring 60 Degrees … Continue reading "60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-15T15:36:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNTk0NyM3MzYyMDY2IzIxODIzMzg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio\",\"datePublished\":\"2026-01-15T15:36:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\\\/\"},\"wordCount\":1129,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNTk0NyM3MzYyMDY2IzIxODIzMzg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\\\/\",\"name\":\"60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNTk0NyM3MzYyMDY2IzIxODIzMzg=\",\"datePublished\":\"2026-01-15T15:36:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNTk0NyM3MzYyMDY2IzIxODIzMzg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyNTk0NyM3MzYyMDY2IzIxODIzMzg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\/","og_locale":"en_US","og_type":"article","og_title":"60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio - Market Newsdesk","og_description":"WASHINGTON, Jan. 15, 2026 (GLOBE NEWSWIRE) — 60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) (\u201c60 Degrees Pharma\u201d or the \u201cCompany\u201d), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it will effect a one-for-four (1:4) reverse stock split (the “reverse split”) of its common stock, par value $0.0001 per share (the “Common Stock”), that will become effective on January 20, 2026, at 12:01 AM Eastern Time, before the opening of trading on The Nasdaq Capital Market (“Nasdaq”). 60 Degrees Pharma has requested that its Common Stock begin trading on January 20, 2026, on a post-reverse split basis on the Nasdaq under the existing symbol “SXTP”. The reverse split is primarily intended to bring 60 Degrees … Continue reading \"60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-15T15:36:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNTk0NyM3MzYyMDY2IzIxODIzMzg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio","datePublished":"2026-01-15T15:36:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\/"},"wordCount":1129,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNTk0NyM3MzYyMDY2IzIxODIzMzg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\/","name":"60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNTk0NyM3MzYyMDY2IzIxODIzMzg=","datePublished":"2026-01-15T15:36:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNTk0NyM3MzYyMDY2IzIxODIzMzg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNTk0NyM3MzYyMDY2IzIxODIzMzg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/60-degrees-pharmaceuticals-inc-announces-approval-of-reverse-stock-split-ratio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/927660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=927660"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/927660\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=927660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=927660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=927660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}